Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

Myricetin inhibits interferon-gamma-induced PD-L1 and IDO1 expression in lung cancer cells


Gu,  Lei
Epigenetics, Max Planck Institute for Heart and Lung Research, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Chen, Y.-C., He, X.-L., Qi, L., Shi, W., Yuan, L.-W., Huang, M.-Y., et al. (2022). Myricetin inhibits interferon-gamma-induced PD-L1 and IDO1 expression in lung cancer cells. BIOCHEMICAL PHARMACOLOGY, 197: 114940. doi:10.1016/j.bcp.2022.114940.

Cite as: https://hdl.handle.net/21.11116/0000-000A-2AAB-7
Programmed death ligand-1 (PD-L1) and indoleamine 2, 3-dioxygenase 1 (IDO1) are immune checkpoints induced by interferon-gamma (IFN-gamma) in the tumor microenvironment, leading to immune escape of tumors. Myricetin (MY) is a flavonoid distributed in many edible and medicinal plants. In this study, MY was identified to inhibit IFN-gamma-induced PD-L1 expression in human lung cancer cells. It also reduced the expression of IDO1 and the production of kynurenine which is the product catalyzed by IDO1, while didn't show obvious effect on the expression of major histocompatibility complex-I (MHC-I), a crucial molecule for antigen presentation. In addition, the function of T cells was evaluated using a co-culture system consist of lung cancer cells and the Jurkat-PD-1 T cell line overexpressing PD-1. MY restored the survival, proliferation, CD69 expression and interleukin-2 (IL-2) secretion of Jurkat-PD-1 T cells suppressed by IFN-gamma-treated lung cancer cells. Mechanistically, IFN-gamma up-regulated PD-L1 and IDO1 at the transcriptional level through the JAK-STAT-IRF1 axis, which was targeted and inhibited by MY. Together, our research revealed a new mechanism of MY mediated anti-tumor activity and highlighted the potential implications of MY in tumor immunotherapy.